Advances in ovarian cancer chemotherapy

Current Opinion in Oncology

Volumn 12, Issue 5, 2000, Pages 481-491

  Deppe, Gunter ^a   Baumann, Peter ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; 3 PHENYLACETAMIDO 2,6 PIPERIDINEDIONE; ALTRETAMINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTON AS2-1; BRYOSTATIN; CARBOPLATIN; CELL ADHESION MOLECULE; CGP 69846A; CISPLATIN; CYTOKINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; EXATECAN; GEMCITABINE; GROWTH FACTOR; IFOSFAMIDE; IM 862; INTERFERON; MELPHALAN; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SCH 58500; TAMOXIFEN; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADOPTIVE IMMUNOTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; FEMALE; GENE THERAPY; GERM CELL TUMOR; HUMAN; ONCOGENE C ERB; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; REVIEW; SURVIVAL TIME; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 0034457348     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200009000-00016     Document Type: Review

References (47)

1. Cancer statistics
2. Limited stage ovarian cancer
3. Management of early ovarian cancer
4. CANCERNET-PDQ [database online]
5. Paclitaxel plus carboplatin in the treatment of ovarian cancer
6. Chemotherapy of epithelial ovarian cancer in gynecologic oncology
7. Chemotherapy of advanced ovarian cancer
8. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer (aoc): A hellenic co-operative group study
9. Treatment of refractory and recurrent ovarian cancer
10. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
11. Current initial therapy of stage III and IV ovarian cancer: Challenges for managed care
12. Phase I study of topotecan with carboplatin alternating with paclitaxel via 3 hour infusion in combination with carboplatin in treatment of newly diagnosed ovarian cancer patients
13. The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer: Is it possible only with peripheral blood stem cell support
14. Epirubicin/paclitaxel/carboplatin vs. paclitaxel/carboplatin as first-line treatment in ovarian cancer: Results of a safety interim analysis of the agogineco intergroup trial
15. Sequential couplets of cisplatin (ddp1/Topotecan (top)) and cisplatin/paclitaxel (+) as first line therapy for advanced epithelial ovarian cancer (eoc): An NCIC clinical trials group phase II study
16. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin
17. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy
18. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study
19. Phase II study of vinorelbine in patients with pretreated ovarian cancer: Activity in platinum-resistant disease
20. Phase I/II trial of escalating doses of weekly topotecan as a second or third line regimen for epithelial ovarian cancer
21. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum
22. Docetaxel for patients with ovarian cancer refractory to paclitaxel, an update
23. Phase II study of gemcitabine (2′1, 2′-difluorodeoxycytidine) in previously treated ovarian cancer patients
24. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma
25. High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for solid tumors
26. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modifications by liposomal encapsulation
27. Treatment of gynecologic cancer: The US experience
28. Prolonged oral etoposide as second-line therapy for platinum resistant (PL/ART) and platinum sensitive (PLATS) ovarian carcinoma: A Gynecologic Oncology Group Study
29. Interim analysis of a non-comparative, multi-center study of doxil/caelyx in the treatment of patients with refractory ovarian cancer
30. A randomized multi-center study of single agent paclitaxel (Taxol) given weekly vs. every three weeks to patients with ovarian cancer previously treated with platinum therapy
31. Phase II study of 72 hr 9-aminocamptothecin (9AC) infusion in second-line therapy of ovarian cancer (a NYGOG and ECOG study)
32. Preliminary results of Cleveland Clinic Cancer Center Gynecologic Oncology Program phase 2 trial of topotecan (topo) administered on a 3-day schedule as salvage therapy of platinum and paclitaxel refractory ovarian cancer (ROC)
33. Carboplatin reinduction after taxane in patients with platinum refractory epithelial ovarian cancer
34. Intraperitoneal therapy of ovarian cancer
35. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: A randomized trial of the Gruppo Oncologico Nord-Oviest
36. Multiple cycles of high-dose chemotherapy for ovarian cancer
37. Gene therapy for ovarian carcinoma
38. Biological therapy of ovarian cancer: Current directions
39. Ovarian germ cell tumors: An update
40. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide and cisplatin
41. Radiotherapy or chemotherapy in malignant stromal tumors of the ovary
42. Systemic therapy
43. Bleomycin, etoposide and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group Study
44. Review of the granulosa thecor cell tumors from the Emil Novak Ovarian Tumor Registry
45. Treatment of metastatic stromal tumors of the ovary with cisplating, doxorubicin and cyclophosphamide
46. Cisplatin, vinblastine and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary
47. An active chemotherapy regimen for advanced ovarian sex-cord stromal tumors